Cargando…

Craniopharyngioma and Metabolic Syndrome: A 5-Year Follow-Up Single-Center Experience

Patients with craniopharyngioma often have comorbidities, such as obesity and hypopituitarism. These two conditions affect each other and worsen the quality of life of patients, which lead to a higher risk of morbidity and mortality. In addition, abdominal obesity, measured as waist circumference (W...

Descripción completa

Detalles Bibliográficos
Autores principales: Scarano, Elisabetta, Solari, Domenico, Riccio, Enrico, Arianna, Rossana, Somma, Teresa, Cavallo, Luigi Maria, Romano, Fiammetta, Colao, Annamaria, Di Somma, Carolina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959765/
https://www.ncbi.nlm.nih.gov/pubmed/35356458
http://dx.doi.org/10.3389/fneur.2022.783737
_version_ 1784677231639920640
author Scarano, Elisabetta
Solari, Domenico
Riccio, Enrico
Arianna, Rossana
Somma, Teresa
Cavallo, Luigi Maria
Romano, Fiammetta
Colao, Annamaria
Di Somma, Carolina
author_facet Scarano, Elisabetta
Solari, Domenico
Riccio, Enrico
Arianna, Rossana
Somma, Teresa
Cavallo, Luigi Maria
Romano, Fiammetta
Colao, Annamaria
Di Somma, Carolina
author_sort Scarano, Elisabetta
collection PubMed
description Patients with craniopharyngioma often have comorbidities, such as obesity and hypopituitarism. These two conditions affect each other and worsen the quality of life of patients, which lead to a higher risk of morbidity and mortality. In addition, abdominal obesity, measured as waist circumference (WC), is together with other parameters [arterial hypertension, hyperglycemia, hypertriglyceridemia, and reduced levels of high-density lipoprotein (HDL) cholesterol], one of the components of metabolic syndrome (MS). Each one of these morbidities occurs in patients with craniopharyngioma more frequently than in the remaining population. On these bases, we evaluated metabolic parameters in patients with craniopharyngioma at the time of diagnosis and after a 5-year follow-up, which compares these data with those of age-, gender-, WC-, and body mass index (BMI)-matched controls. In addition, we evaluated the prevalence of MS according to IDF criteria (MS-IDF) and the prevalence of MS according to ATP III (MS-ATPIII) criteria in patients and controls at baseline and after 5 years. We recruited 20 patients with craniopharyngioma (age 38.5 ± 15 years, 10 M) and 20 age-, gender-, WC- and BMI-matched controls (age 34.16 ± 13.19 years, 10 M). In all patients and controls, we evaluated the following: anthropometric features [height, weight, BMI, WC, hip circumference (HC) and waist-to-hip ratio (WHR)], systolic blood pressure (SBP) and diastolic blood pressure (DBP), lipid profile [total cholesterol (TC), HDL, low-density lipoprotein (LDL) cholesterol, triglycerides (TG)], and blood glucose at baseline and after 5 years. The prevalence of MS, according to IDF and ATPIII criteria, was calculated in the two groups at baseline and after 5 years. According to our results, at baseline, patients with craniopharyngioma had a worse metabolic profile than controls and a higher prevalence of MS. Besides, at a 5-year follow-up, patients still had impaired metabolic characteristics and more frequent MS (according to IDF and ATPIII criteria) when compared to controls. These data confirm that MS in patients with craniopharyngioma is unresponsive to life-changing interventions and to a common pharmacological approach. Other factors may be involved in the evolution of these conditions; so, further studies are needed to establish the correct management of these patients.
format Online
Article
Text
id pubmed-8959765
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89597652022-03-29 Craniopharyngioma and Metabolic Syndrome: A 5-Year Follow-Up Single-Center Experience Scarano, Elisabetta Solari, Domenico Riccio, Enrico Arianna, Rossana Somma, Teresa Cavallo, Luigi Maria Romano, Fiammetta Colao, Annamaria Di Somma, Carolina Front Neurol Neurology Patients with craniopharyngioma often have comorbidities, such as obesity and hypopituitarism. These two conditions affect each other and worsen the quality of life of patients, which lead to a higher risk of morbidity and mortality. In addition, abdominal obesity, measured as waist circumference (WC), is together with other parameters [arterial hypertension, hyperglycemia, hypertriglyceridemia, and reduced levels of high-density lipoprotein (HDL) cholesterol], one of the components of metabolic syndrome (MS). Each one of these morbidities occurs in patients with craniopharyngioma more frequently than in the remaining population. On these bases, we evaluated metabolic parameters in patients with craniopharyngioma at the time of diagnosis and after a 5-year follow-up, which compares these data with those of age-, gender-, WC-, and body mass index (BMI)-matched controls. In addition, we evaluated the prevalence of MS according to IDF criteria (MS-IDF) and the prevalence of MS according to ATP III (MS-ATPIII) criteria in patients and controls at baseline and after 5 years. We recruited 20 patients with craniopharyngioma (age 38.5 ± 15 years, 10 M) and 20 age-, gender-, WC- and BMI-matched controls (age 34.16 ± 13.19 years, 10 M). In all patients and controls, we evaluated the following: anthropometric features [height, weight, BMI, WC, hip circumference (HC) and waist-to-hip ratio (WHR)], systolic blood pressure (SBP) and diastolic blood pressure (DBP), lipid profile [total cholesterol (TC), HDL, low-density lipoprotein (LDL) cholesterol, triglycerides (TG)], and blood glucose at baseline and after 5 years. The prevalence of MS, according to IDF and ATPIII criteria, was calculated in the two groups at baseline and after 5 years. According to our results, at baseline, patients with craniopharyngioma had a worse metabolic profile than controls and a higher prevalence of MS. Besides, at a 5-year follow-up, patients still had impaired metabolic characteristics and more frequent MS (according to IDF and ATPIII criteria) when compared to controls. These data confirm that MS in patients with craniopharyngioma is unresponsive to life-changing interventions and to a common pharmacological approach. Other factors may be involved in the evolution of these conditions; so, further studies are needed to establish the correct management of these patients. Frontiers Media S.A. 2022-03-09 /pmc/articles/PMC8959765/ /pubmed/35356458 http://dx.doi.org/10.3389/fneur.2022.783737 Text en Copyright © 2022 Scarano, Solari, Riccio, Arianna, Somma, Cavallo, Romano, Colao and Di Somma. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Scarano, Elisabetta
Solari, Domenico
Riccio, Enrico
Arianna, Rossana
Somma, Teresa
Cavallo, Luigi Maria
Romano, Fiammetta
Colao, Annamaria
Di Somma, Carolina
Craniopharyngioma and Metabolic Syndrome: A 5-Year Follow-Up Single-Center Experience
title Craniopharyngioma and Metabolic Syndrome: A 5-Year Follow-Up Single-Center Experience
title_full Craniopharyngioma and Metabolic Syndrome: A 5-Year Follow-Up Single-Center Experience
title_fullStr Craniopharyngioma and Metabolic Syndrome: A 5-Year Follow-Up Single-Center Experience
title_full_unstemmed Craniopharyngioma and Metabolic Syndrome: A 5-Year Follow-Up Single-Center Experience
title_short Craniopharyngioma and Metabolic Syndrome: A 5-Year Follow-Up Single-Center Experience
title_sort craniopharyngioma and metabolic syndrome: a 5-year follow-up single-center experience
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8959765/
https://www.ncbi.nlm.nih.gov/pubmed/35356458
http://dx.doi.org/10.3389/fneur.2022.783737
work_keys_str_mv AT scaranoelisabetta craniopharyngiomaandmetabolicsyndromea5yearfollowupsinglecenterexperience
AT solaridomenico craniopharyngiomaandmetabolicsyndromea5yearfollowupsinglecenterexperience
AT riccioenrico craniopharyngiomaandmetabolicsyndromea5yearfollowupsinglecenterexperience
AT ariannarossana craniopharyngiomaandmetabolicsyndromea5yearfollowupsinglecenterexperience
AT sommateresa craniopharyngiomaandmetabolicsyndromea5yearfollowupsinglecenterexperience
AT cavalloluigimaria craniopharyngiomaandmetabolicsyndromea5yearfollowupsinglecenterexperience
AT romanofiammetta craniopharyngiomaandmetabolicsyndromea5yearfollowupsinglecenterexperience
AT colaoannamaria craniopharyngiomaandmetabolicsyndromea5yearfollowupsinglecenterexperience
AT disommacarolina craniopharyngiomaandmetabolicsyndromea5yearfollowupsinglecenterexperience